2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117162
    S 1432 24932-86-3 98%
    S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs.
    S 1432
  • HY-117176
    KRP-199 221164-28-9 98%
    KRP-199 (compound 14h) is an α-amino-3-hydroxy-5-methylisoxazolepropionic acid receptor (AMPA-R) antagonist (Ki=16 nM) with high potency and selectivity for AMPA-R in vitro and good neuroprotective effects in vivo. KRP-199 can be used in the study of neurodegenerative diseases.
    KRP-199
  • HY-117223
    GEA 857 120493-42-7 98%
    GEA 857 is a structural analog of the Serotonin (HY-B1473A) uptake blocker Alaproclate (HY-164011). GEA 857 enhances responses induced by muscarinic receptor agonists by inhibiting certain calcium-dependent potassium channels on membranes, a blockade that can enhance or prolong the muscarinic cholinergic effects. GEA 857 can be used in research on neurodegenerative diseases.
    GEA 857
  • HY-117248
    SR-3737 1164153-37-0 98%
    SR-3737 is a JNK3 and p38 inhibitor (IC50: 12 and 3 nM).
    SR-3737
  • HY-117251
    LP-403812 1142050-84-7 98%
    LP-403812 is a high affinity proline transporter (PROT) inhibitor that produces dose-dependent inhibition of hPROT (IC50=0.11 μM; Ki=0.12 μM) and also inhibits the activity of mouse brain synaptosomal mPROT with the same potency (IC50=0.23 μM). LP-403812 can be used to study the function of PROT in the brain.
    LP-403812
  • HY-117281
    Moexipril 103775-10-6 98%
    Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects-.
    Moexipril
  • HY-117284
    Eucatropine 100-91-4 98%
    Eucatropine is a potent muscarinic acetylcholine receptor (mAChR) inhibitor with an IC50 value of 0.583 μM. Eucatropine is an anticholinergic agent.
    Eucatropine
  • HY-117381
    γ-secretase-IN-2 564462-36-8 98%
    γ-secretase-IN-2 (Compound 34) is an inhibitor for γ-secretase, with an IC50 of 0.06 nM. γ-secretase-IN-2 can be used for the study of Alzheimer's disease.
    γ-secretase-IN-2
  • HY-117467
    BMT-108908 1801151-15-4 98%
    BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power.
    BMT-108908
  • HY-117471
    Antiarrhythmic agent-3 21236-52-2 98%
    Antiarrhythmic agent-3 is an antiarrhythmic drug with the activity of enhancing antiarrhythmic efficacy and improving inhibition index. The antiarrhythmic effect of antiarrhythmic agent-3 is related to its hydrophobicity (log P). The central nervous system toxicity of antiarrhythmic agent-3 is related to the combined effect of its hydrophobicity and acid constant (pKa).
    Antiarrhythmic agent-3
  • HY-117497
    Simetride 154-82-5 98%
    Simetride is an analgesic agent. Simeicui is used for pain relief.
    Simetride
  • HY-117507
    U92016A hydrochloride 149654-41-1 98%
    U92016A hydrochloride is a potent, metabolically stable, orally acitive 5-HT1A receptor agonist with an exceptionally high degree of intrinsic activity. U92016A hydrochloride binds with high affinity to human 5-HT1A receptors expressed in Chinese hamster ovary cells (Ki=0.2 nM).
    U92016A hydrochloride
  • HY-117526
    (-)-Mesembrine 24880-43-1 98%
    (-)-Mesembrine, a psychoactive alkaloid, is a partial racemate in S. strictum and S. tortuosum in smaller amounts.
    (-)-Mesembrine
  • HY-117533
    UNC0006 1354030-14-0 98%
    UNC0006 is a β-arrestin-biased dopamine D2 ligand. UNC0006 can be used in the study of antipsychotic.
    UNC0006
  • HY-117542
    D595 16740-29-7 98%
    D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers.
    D595
  • HY-117560
    PWZ-029 164025-33-6 98%
    PWZ-029 is a selective inverse agonist for α5 GABAA receptors. PWZ-029 can improve object recognition in normal and scopolamine-treated rat model.
    PWZ-029
  • HY-117575
    WAY-100135 133025-23-7 98%
    WAY-100135 is a serotonergic compound belonging to the phenylpiperazine family, utilized in scientific research for its role as a strong antagonist of the 5-HT1A receptor and a partial agonist of the 5-HT1D receptor, with minimal activity at the 5-HT1B receptor.
    WAY-100135
  • HY-117578
    KB 5666 131916-69-3 98%
    KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia.
    KB 5666
  • HY-117606
    LY3027788 1377615-76-3 98%
    LY3027788, a diester analog of LY3020371 which is an mGlu2/3 receptor antagonist, is a potent and orally active prodrug of LY3020371. LY3027788 has antidepressant efficacy.
    LY3027788
  • HY-117609
    UE2343 1346013-80-6 98%
    UE2343 is an orally available, brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. UE2343 is being investigated for the treatment of Alzheimer's disease.
    UE2343
Cat. No. Product Name / Synonyms Application Reactivity